SCHEMBL2748639

SCHEMBL2748639

Nc1nc2c(F)c(F)ccc2s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.61
LMNA P02545 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
PDPK1 O15530 1/20 0.47
PDE10A Q9Y233 1/20 0.47
CYP3A4 P08684 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
AXL P30530 1/20 0.43
GFER P55789 1/20 0.43
HSD17B10 Q99714 1/20 0.39
NSD1 Q96L73 1/20 0.37
GAA P10253 2/20 0.36
MAPT P10636 2/20 0.36
EPHX2 P34913 1/20 0.36
SCN4A P35499 1/20 0.36
RAB9A P51151 1/20 0.35
KDM4E B2RXH2 1/20 0.35
HTT P42858 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PIK3CD O00329 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30904497 1.00 ALDH1A1 (0.61) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL30521262 0.81 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL30829728 0.81 SMN1; SMN2 (0.62) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL30231203 0.81 SMN1; SMN2 (0.58) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL28902805 0.81 SMN1; SMN2 (0.58) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL24425191 0.81 SMN1; SMN2 (0.62) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL31389818 0.81 SMN1; SMN2 (0.58) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL34471393 0.81 LMNA (0.58) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL21712337 0.81 ALDH1A1 (0.53) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A
SCHEMBL6118333 0.80 SMN1; SMN2 (0.59) ALDH1A1LMNASMN1; SMN2PDPK1PDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180037817-A1 POLYMERIZABLE COMPOSITION AND OPTICALLY ANISOTROPIC BODY DIC CORPORATION (JP) 2018-02-08 US disclosed
US-8178668-B2 2-aminopyridine kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-05-15 US disclosed
EP-2265270-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009099982-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197862-A1 2-AMINOPYRIDINE KINASE INHIBITORS ERBB2, ABL2, TIE1 ALDH1A1 945/4885LMNA 3582/4885SMN1; SMN2 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.